Sutro Biopharma’s (STRO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a research report released on Wednesday morning, Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright also issued estimates for Sutro Biopharma’s Q3 2024 earnings at ($0.65) EPS, Q4 2024 earnings at ($0.69) EPS, […]

Leave a Reply

Your email address will not be published.

Previous post FY2025 EPS Estimates for Hillenbrand, Inc. Decreased by Analyst (NYSE:HI)
Next post Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Chardan Capital